Susceptibility of Patients With Inflammatory Bowel Disease to Covid-19 Compared With Their Households

Susceptibility of Patients With Inflammatory Bowel Disease to Covid-19 Compared With Their Households Publisher

Anushiravani A¹ ; Saberzadehardestani B¹ ; Vahedi H¹ ; Fakheri H² ; Mansourghanaei F³ ; Maleki I² ; Nasserimoghaddam S¹ ; Vosoghinia H⁴ ; Ghadir MR⁵ ; Hormati A^{5, 6} ; Kasaeian A^{1, 7} ; Radmard AR⁸ ; Khosravi B¹ ; Malekzadeh M¹ Show All Authors

Anushiravani A¹
Saberzadehardestani B¹
Vahedi H¹
Fakheri H²
Mansourghanaei F³
Maleki I²
Nasserimoghaddam S¹
Vosoghinia H⁴
Ghadir MR⁵
Hormati A^{5, 6}
Kasaeian A^{1, 7}
Radmard AR⁸
Khosravi B¹
Malekzadeh M¹
Alatab S¹
Sadeghi A¹
Aminisani N⁹
Poustchi H¹
Sima AR¹
Malekzadeh R¹

Show Affiliations

1. Digestive Disease Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
2. Gut and Liver Research Center, Mazandaran University of Medical Sciences, Sari, Iran
3. Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran
4. Gastroenterology and Hematology Department, Faculty of Medicine, Ghaem Hospital, Mashhad, Iran
5. Gastroenterology and Hepatology Diseases Research Center, Qom University of Medical Science, Iran
6. Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran
7. Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
8. Department of Radiology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
9. Department of Epidemiology and Statistics, Faculty of Health Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran

Source: Middle East Journal of Digestive Diseases Published:2022

Abstract

BACKGROUND: Immunosuppressive agents used in the treatment of inflammatory bowel diseases (IBDs) could potentially increase the risk of coronavirus disease 2019 (COVID-19). We aimed to compare COVID-19 frequency in patients with IBD with their households and identify the related risk factors. METHODS: Firstly, a multi-centered, observational study on 2110 patients with IBD and 2110 age-matched household members was conducted to compare COVID-19 frequency. Secondly, the data of patients with IBD and COVID-19 who had called the COVID-19 hotline were added. Multivariable logistic regression was used to evaluate the effect of age, type and severity of IBD, the number of comorbidities, and medications on the frequency of COVID-19 among the patients with IBD. RESULTS: The prevalence of COVID-19 in patients with IBD and household groups was similar (34 [1.61%] versus 35 [1.65%]; P = 0.995). The prevalence of COVID-19 increased from 2.1% to 7.1% in those with three or more comorbidities (P = 0.015) and it was significantly higher in those with severe IBD (P = 0.026). The multivariable analysis only showed a significant association with anti-TNF monotherapy (OR: 2.5, CI: 0.97-6.71, P = 0.05), and other medications were not associated with COVID-19. CONCLUSION: The prevalence of COVID-19 in patients with IBD was similar to the household members. Only patients with IBD receiving anti-TNF monotherapy had a higher risk of COVID-19 susceptibility. This finding could be attributed to the higher exposure to the virus during administration in health care facilities. © 2022 The Author(s).

Related Docs

View other Related Docs

1. Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: Comparison With Household Members and the Role of Ibd Medications, Archives of Iranian Medicine (2022)

2. Transmembrane Serine Protease 2 and Angiotensin-Converting Enzyme 2 Anti-Inflammatory Receptors for Covid-19/Inflammatory Bowel Diseases Treatment, World Journal of Gastroenterology (2021)

3. Covid-19 and Multiorgan Failure: A Narrative Review on Potential Mechanisms, Journal of Molecular Histology (2020)

4. Factors Associated With Covid-19 Morbidity and Mortality: A Narrative Review, Journal of Iranian Medical Council (2020)

5. Potential Antiviral Immune Response Against Covid-19: Lessons Learned From Sars-Cov, Advances in Experimental Medicine and Biology (2021)

6. An Overview on the Seven Pathogenic Human Coronaviruses, Reviews in Medical Virology (2022)

7. Association Between Inflammatory Bowel Disease and Viral Infections, Current Microbiology (2023)

8. Host Factors: Implications in Immunopathogenesis of Covid-19, Pathology Research and Practice (2021)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (3)

Reza Malekzadeh (1)

Style	Citing Format
MLA	Anushiravani A, et al.. "Susceptibility of Patients With Inflammatory Bowel Disease to Covid-19 Compared With Their Households." Middle East Journal of Digestive Diseases, vol. 14, no. 2, 2022, pp. 182-191.
APA	Anushiravani A, Saberzadehardestani B, Vahedi H, Fakheri H, Mansourghanaei F, Maleki I, Nasserimoghaddam S, Vosoghinia H, Ghadir MR, Hormati A, Kasaeian A, Radmard AR, Khosravi B, Malekzadeh M, Alatab S, Sadeghi A, Aminisani N, Poustchi H, Sima AR, Malekzadeh R (2022). Susceptibility of Patients With Inflammatory Bowel Disease to Covid-19 Compared With Their Households. Middle East Journal of Digestive Diseases, 14(2), 182-191.
Chicago	Anushiravani A, Saberzadehardestani B, Vahedi H, Fakheri H, Mansourghanaei F, Maleki I, Nasserimoghaddam S, et al.. "Susceptibility of Patients With Inflammatory Bowel Disease to Covid-19 Compared With Their Households." Middle East Journal of Digestive Diseases 14, no. 2 (2022): 182-191.
Harvard	Anushiravani A et al. (2022) 'Susceptibility of Patients With Inflammatory Bowel Disease to Covid-19 Compared With Their Households', Middle East Journal of Digestive Diseases, 14(2), pp. 182-191.
Vancouver	Anushiravani A, Saberzadehardestani B, Vahedi H, Fakheri H, Mansourghanaei F, Maleki I, et al.. Susceptibility of Patients With Inflammatory Bowel Disease to Covid-19 Compared With Their Households. Middle East Journal of Digestive Diseases. 2022;14(2):182-191.
BibTex	@article{ author = {Anushiravani A and Saberzadehardestani B and Vahedi H and Fakheri H and Mansourghanaei F and Maleki I and Nasserimoghaddam S and Vosoghinia H and Ghadir MR and Hormati A and Kasaeian A and Radmard AR and Khosravi B and Malekzadeh M and Alatab S and Sadeghi A and Aminisani N and Poustchi H and Sima AR and Malekzadeh R}, title = {Susceptibility of Patients With Inflammatory Bowel Disease to Covid-19 Compared With Their Households}, journal = {Middle East Journal of Digestive Diseases}, volume = {14}, number = {2}, pages = {182-191}, year = {2022} }
RIS	TY - JOUR AU - Anushiravani A AU - Saberzadehardestani B AU - Vahedi H AU - Fakheri H AU - Mansourghanaei F AU - Maleki I AU - Nasserimoghaddam S AU - Vosoghinia H AU - Ghadir MR AU - Hormati A AU - Kasaeian A AU - Radmard AR AU - Khosravi B AU - Malekzadeh M AU - Alatab S AU - Sadeghi A AU - Aminisani N AU - Poustchi H AU - Sima AR AU - Malekzadeh R TI - Susceptibility of Patients With Inflammatory Bowel Disease to Covid-19 Compared With Their Households JO - Middle East Journal of Digestive Diseases VL - 14 IS - 2 SP - 182 EP - 191 PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract